Opus Genetics IRD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.16M-50.6% | $3.87M-10.2% | $3.08M-20.4% | $2.88M+159% | $4.37M+155% | ||
| $10.58M+33.0% | —— | $6.41M-28.6% | —— | $7.95M— | ||
| $5.94M-6.3% | $4.89M-33.0% | $4.98M+72.1% | $5.77M+71.9% | $6.35M+35.9% | ||
| $16.52M+15.5% | $15.32M-63.8% | $11.39M-4.1% | $11.79M+24.9% | $14.3M+51.8% | ||
| -$14.36M-44.7% | -$11.45M+69.9% | -$8.31M-3.8% | -$8.91M-6.9% | -$9.93M-28.8% | ||
| -665.9%-439pp | -296.3%+588pp | -269.9%-62.8pp | -309%+440pp | -227.2%+223pp | ||
| $69K— | $61K— | $68K— | $0— | $0— | ||
| $844K+179% | $703K-75.1% | $450K-6.8% | $534K-5.2% | $302K-49.8% | ||
| -$65.54M-700% | -$16.52M+53.0% | -$17.45M-132% | -$7.42M+4.4% | -$8.19M-15.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$65.54M-700% | -$16.52M+53.0% | -$17.45M-132% | -$7.42M+4.4% | -$8.19M-15.3% | ||
| -3,038.2%-2,851pp | -427.5%+389pp | -566.9%-372pp | -257.5%+441pp | -187.5%+228pp | ||
| -$0.75-213% | -$0.21+83.5% | -$0.25+13.8% | -$0.12+60.0% | -$0.24+17.2% | ||
| -$14.35M-44.7% | -$11.44M+69.9% | -$8.3M-3.6% | -$8.89M-6.8% | -$9.92M-28.6% | ||
| -665.3%-438pp | -296%+588pp | -269.5%-62.4pp | -308.5%+440pp | -226.9%+224pp | ||
| -$14.36M-44.7% | -$11.45M+69.9% | -$8.31M-3.8% | -$8.91M-6.9% | -$9.93M-28.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Opus Genetics's revenue?
- Opus Genetics (IRD) generated $12.0M in revenue over the trailing twelve months, down 12.2% year over year.
- Is Opus Genetics profitable?
- Opus Genetics is not currently profitable: it reported a net loss of $106.9M over the trailing twelve months, a -892.4% net margin.
- What is Opus Genetics's earnings per share?
- Opus Genetics's diluted EPS over the trailing twelve months is $-1.33.
- Where does Opus Genetics's income statement data come from?
- Every line is extracted from Opus Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
